Cooperation between VEGF and beta3 integrin during cardiac vascular development
- PMID: 17062734
- PMCID: PMC1801042
- DOI: 10.1182/blood-2005-10-038893
Cooperation between VEGF and beta3 integrin during cardiac vascular development
Abstract
In the developing myocardium, vascular endothelial growth factor (VEGF)-dependent neovascularization occurs by division of existing vessels, a process that persists for several weeks following birth. During this remodeling phase, mRNA expression of beta3 integrin in the heart decreases significantly as vessel maturation progresses. However, in male mice lacking beta3, coronary capillaries fail to mature and continue to exhibit irregular endothelial thickness, endothelial protrusions into the lumen, and expanded cytoplasmic vacuoles. Surprisingly, this phenotype was not seen in female beta3-null mice. Enhanced VEGF signaling contributes to the beta3-null phenotype, because these vessels can be normalized by inhibitors of VEGF or Flk-1. Moreover, intravenous injection of VEGF induces a similar angiogenic phenotype in hearts of adult wild-type mice. These findings show a clear vascular phenotype in the hearts of mice lacking beta3 and suggest this integrin plays a critical role in coronary vascular development and the vascular response to VEGF.
Figures
References
-
- Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science. 1994;264:569–571. - PubMed
-
- Brooks PC, Montgomery AM, Rosenfeld M, et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 1994;79:1157–1164. - PubMed
-
- Reynolds AR, Reynolds LE, Nagel TE, et al. Elevated Flk1 (vascular endothelial growth factor receptor 2) signaling mediates enhanced angiogenesis in beta3-integrin-deficient mice. Cancer Res. 2004;64:8643–8650. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 CA095262/CA/NCI NIH HHS/United States
- R37 CA050286/CA/NCI NIH HHS/United States
- HL78912/HL/NHLBI NIH HHS/United States
- CA95262/CA/NCI NIH HHS/United States
- R01 HL078912/HL/NHLBI NIH HHS/United States
- R01 CA050286/CA/NCI NIH HHS/United States
- CA50286/CA/NCI NIH HHS/United States
- HL57900/HL/NHLBI NIH HHS/United States
- 1F32HL69701/HL/NHLBI NIH HHS/United States
- R01 CA045726/CA/NCI NIH HHS/United States
- F32 HL069701/HL/NHLBI NIH HHS/United States
- P01 HL057900/HL/NHLBI NIH HHS/United States
- CA45726/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
